Razelle Kurzrock, MD, FACP

Publications

• Reply to S. Sorscher.

  (Subbiah V, Kurzrock R.) J Clin Oncol. 2023 Aug 20;41(24):4058-4059 PMID: 37311150 SCOPUS ID: 2-s2.0-85168238088 06/13/2023

• LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics.

  (Adashek JJ, Kato S, Nishizaki D, Miyashita H, De P, Lee S, Pabla S, Nesline M, Conroy JM, DePietro P, Lippman S, Kurzrock R.) Cancer Med. 2023 Jun;12(12):13155-13166 PMID: 37132280 PMCID: PMC10315766 SCOPUS ID: 2-s2.0-85157966158 05/03/2023

• Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.

  (Luke JJ, Fakih M, Schneider C, Chiorean EG, Bendell J, Kristeleit R, Kurzrock R, Blagden SP, Brana I, Goff LW, O'Hayer K, Geschwindt R, Smith M, Zhou F, Naing A.) Br J Cancer. 2023 Jun;128(12):2227-2235 PMID: 37087488 PMCID: PMC10241827 SCOPUS ID: 2-s2.0-85153278562 04/23/2023

• Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.

  (Tateo V, Marchese PV, Mollica V, Massari F, Kurzrock R, Adashek JJ.) Pharmaceuticals (Basel). 2023 Apr 19;16(4) PMID: 37111371 PMCID: PMC10144220 04/28/2023

• Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis

  (Shaya J, Kato S, Adashek JJ, Patel H, Fanta PT, Botta GP, Sicklick JK, Kurzrock R.) npj Genomic Medicine. December 2023;8(1) SCOPUS ID: 2-s2.0-85146753220 12/01/2023

• T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy

  (Miyashita H, Kurzrock R, Bevins NJ, Thangathurai K, Lee S, Pabla S, Nesline M, Glenn ST, Conroy JM, DePietro P, Rubin E, Sicklick JK, Kato S.) npj Genomic Medicine. December 2023;8(1) SCOPUS ID: 2-s2.0-85168289666 12/01/2023

• Tumour mutational burden and survival with molecularly matched therapy

  (de Bortoli T, Benary M, Horak P, Lamping M, Stintzing S, Tinhofer I, Leyvraz S, Schäfer R, Klauschen F, Keller U, Stenzinger A, Fröhling S, Kurzrock R, Keilholz U, Rieke DT, Jelas I.) European Journal of Cancer. September 2023;190 SCOPUS ID: 2-s2.0-85166666044 09/01/2023

• Correlation between biomarkers and treatment outcomes in diverse cancers: a systematic review and meta-analysis of phase I and II immunotherapy clinical trials

  (Fountzilas E, Vo HH, Mueller P, Kurzrock R, Tsimberidou AM.) European Journal of Cancer. August 2023;189 SCOPUS ID: 2-s2.0-85162944700 08/01/2023

• Autoimmune HLA Alleles and Neoepitope Presentation Predict Post-Allogenic Transplant Relapse

  (Castro A, Goodman AM, Rane Z, Talwar JV, Frampton GM, Morris GP, Lippman SM, Zhang X, Kurzrock R, Carter H.) Journal of Immunotherapy and Precision Oncology. 1 August 2023;6(3):127-132 SCOPUS ID: 2-s2.0-85168614607 08/01/2023

• Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload

  (Kondrashov A, Sapkota S, Sharma A, Riano I, Kurzrock R, Adashek JJ.) Pharmaceutics. August 2023;15(8) SCOPUS ID: 2-s2.0-85168866080 08/01/2023

• Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors

  (Luke JJ, Fakih M, Schneider C, Chiorean EG, Bendell J, Kristeleit R, Kurzrock R, Blagden SP, Brana I, Goff LW, O’Hayer K, Geschwindt R, Smith M, Zhou F, Naing A.) British Journal of Cancer. 29 June 2023;128(12):2227-2235 SCOPUS ID: 2-s2.0-85153278562 06/29/2023

• ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.

  (Schubert L, Elliott A, Le AT, Estrada-Bernal A, Doebele RC, Lou E, Borghaei H, Demeure MJ, Kurzrock R, Reuss JE, Ou SI, Braxton DR, Thomas CA, Darabi S, Korn WM, El-Deiry WS, Liu SV.) Front Oncol. 2023;13:1115405 PMID: 37168365 PMCID: PMC10164992 05/12/2023